Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04583280 · ClinicalTrials.gov registry record · Phase 3
A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)
A Phase 3 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 3
- Development phase
- 28
- Enrollment target
NCT04583280 is a Phase 3 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 28 participants.
The verdict
NCT04583280, a Phase 3 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy of rilematovir compared to placebo treatment with respect to the clinical outcome on the RSV Recovery Scale (RRS).
Interventions
- DRUG Placebo
- DRUG Rilematovir
- DRUG Rilematovir X mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2021-09-06 |
| Est. Completion | 2022-03-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04583280
The ClinicalTrials.gov registry entry for NCT04583280 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04583280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04583280 about?
NCT04583280 is a clinical study titled "A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)". The purpose of the study is to evaluate the efficacy of rilematovir compared to placebo treatment with respect to the clinical outcome on the RSV Recovery Scale (RRS).
What is the current status of trial NCT04583280?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 28 participants. The study started on 2021-09-06. Estimated completion is 2022-03-18.
What interventions are being tested in trial NCT04583280?
The interventions under investigation include: Placebo (DRUG), Rilematovir (DRUG), Rilematovir X mg/kg (DRUG).
Who is sponsoring clinical trial NCT04583280?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.